{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:02:51Z","timestamp":1778648571347,"version":"3.51.4"},"reference-count":56,"publisher":"American Veterinary Medical Association (AVMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>OBJECTIVE<\/jats:bold> To determine whether high doses of enalapril and benazepril would be more effective than standard doses of these drugs in suppressing the furosemide-activated renin-angiotensin-aldosterone system (RAAS).<\/jats:p>\n<jats:p><jats:bold>ANIMALS<\/jats:bold> 6 healthy Beagles.<\/jats:p>\n<jats:p><jats:bold>PROCEDURES<\/jats:bold> 2 experiments were conducted; each lasted 10 days, separated by a 2-week washout period. In experiment 1, all dogs received furosemide (2 mg\/kg, PO, q 12 h) and enalapril (1 mg\/kg, PO, q 12 h) for 8 days (days 0 through 7). In experiment 2, dogs received furosemide (2 mg\/kg, PO, q 12 h) and benazepril (1 mg\/kg, PO, q 12 h) for 8 days. Effects on the RAAS were determined by assessing serum angiotensin-converting enzyme (ACE) activity on days \u22121, 3, and 7; serum aldosterone concentration on days \u22122, \u22121, 1, 3, and 7; and the urinary aldosterone-creatinine ratio (UAldo:C) in urine collected in the morning and evening of days \u22122, \u22121, 1, 3, and 7.<\/jats:p>\n<jats:p><jats:bold>RESULTS<\/jats:bold> High doses of enalapril and benazepril caused significant reductions in serum ACE activity on all days but were not more effective than standard doses used in other studies. Mean UAldo:C remained significantly higher on days 2 through 7, compared with baseline values. Serum aldosterone concentration also increased after drug administration, which mirrored changes in the UAldo:C.<\/jats:p>\n<jats:p><jats:bold>CONCLUSIONS AND CLINICAL RELEVANCE<\/jats:bold> In this study, administration of high doses of enalapril and benazepril significantly inhibited ACE activity, yet did not prevent increases in mean urine and serum aldosterone concentrations resulting from furosemide activation of RAAS. This suggested that aldosterone breakthrough from ACE inhibition was a dose-independent effect of ACE inhibitors.<\/jats:p>","DOI":"10.2460\/ajvr.76.12.1041","type":"journal-article","created":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T15:32:56Z","timestamp":1448897576000},"page":"1041-1050","source":"Crossref","is-referenced-by-count":23,"title":["Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs"],"prefix":"10.2460","volume":"76","author":[{"given":"Marisa K.","family":"Ames","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarke E.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunggon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea C.","family":"Lantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"zumBrunnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Am J Cardiol","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/0002-9149(82)90243-0","article-title":"Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure","volume":"49","author":"Levine","year":"1982"},{"key":"ref2","series-title":"Eur Heart J","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/oxfordjournals.eurheartj.a059429","article-title":"Neuroendocrine response in acute heart failure and the influence of treatment","volume":"10","author":"Broqvist","year":"1989"},{"key":"ref3","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure","volume":"82","author":"Francis","year":"1990"},{"key":"ref4","series-title":"Eur J Heart Fail","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2013"},{"key":"ref5","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac in-terstitium: fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991"},{"key":"ref6","series-title":"Hypertension","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1161\/01.HYP.19.3.270","article-title":"Aldosterone reduces baroreceptor discharge in the dog","volume":"19","author":"Wang","year":"1992"},{"issue":"suppl O","key":"ref7","series-title":"Eur Heart J","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/eurheartj\/16.suppl_O.107","article-title":"The renin-angiotensin-aldosterone system and myocardial collagen matrix remodeling in congestive heart failure","volume":"16","author":"Brilla","year":"1995"},{"issue":"suppl N","key":"ref8","series-title":"Eur Heart J","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/eurheartj\/16.suppl_N.98","article-title":"Aldosterone and heart failure","volume":"16","author":"Zannad","year":"1995"},{"key":"ref9","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001"},{"key":"ref10","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999"},{"key":"ref11","series-title":"Cardiovasc Drugs Ther","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10557-010-6256-6","article-title":"Aldosterone inhibition and cardiovascular protection: more important than it once appeared","volume":"24","author":"Martinez","year":"2010"},{"key":"ref12","series-title":"Am J Med Sci","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MAJ.0b013e3182327527","article-title":"Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: part II","volume":"342","author":"Dube","year":"2011"},{"key":"ref13","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/01.CIR.63.3.645","article-title":"Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure","volume":"63","author":"Dzau","year":"1981"},{"key":"ref14","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2460\/ajvr.2001.62.1793","article-title":"Additive effects of a sodium chloride restricted diet and furosemide administration in healthy dogs","volume":"62","author":"Lovern","year":"2001"},{"key":"ref15","series-title":"J Vet Pharmacol Ther","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1365-2885.2007.00894.x","article-title":"The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog","volume":"30","author":"Atkins","year":"2007"},{"key":"ref16","series-title":"J Vet Intern Med","first-page":"243","article-title":"Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group","volume":"9","year":"1995"},{"key":"ref17","series-title":"J Am Vet Med Assoc","first-page":"1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally acquired heart failure","volume":"213","author":"Ettinger","year":"1998"},{"key":"ref18","series-title":"J Vet Cardiol","first-page":"7","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomised, double-blinded, placebo-controlled, long term clinical trial","volume":"1","year":"1999"},{"key":"ref19","series-title":"J Vet Cardiol","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1760-2734(06)70053-4","article-title":"Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure","volume":"6","author":"Amberger","year":"2004"},{"key":"ref20","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009"},{"key":"ref21","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999"},{"key":"ref22","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003"},{"key":"ref23","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011"},{"key":"ref24","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"Bernay","year":"2010"},{"key":"ref25","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2460\/ajvr.72.12.1646","article-title":"Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs","volume":"72","author":"Lantis","year":"2011"},{"key":"ref26","series-title":"J Vet Pharmacol Ther","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jvp.12154","article-title":"Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs","volume":"38","author":"Lantis","year":"2015"},{"key":"ref27","series-title":"J Vet Cardiol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvc.2006.11.001","article-title":"Estimation of 24-h aldosterone secretion in the dog using the urine aldosterone:creatinine ratio","volume":"9","author":"Gardner","year":"2007"},{"key":"ref28","series-title":"Heart","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999"},{"key":"ref29","series-title":"Eur J Heart Fail","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1388-9842(99)00046-X","article-title":"Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study","volume":"1","author":"Lee","year":"1999"},{"key":"ref30","series-title":"Curr Hypertens Rep","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11906-000-0027-x","article-title":"Spironolactone in congestive heart failure","volume":"2","author":"Soberman","year":"2000"},{"key":"ref31","series-title":"Nat Clin Pract Nephrol","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007"},{"key":"ref32","series-title":"J Am Soc Hypertens","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jash.2012.07.003","article-title":"Aldosterone breakthrough during aliskiren, valsartan, and combination (alisiren + valsartan) therapy","volume":"6","author":"Bomback","year":"2012"},{"key":"ref33","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2460\/ajvr.74.8.1084","article-title":"Effect of high-dosage pimobendan administration on the renin-angiotensin-aldosterone system in dogs","volume":"74","author":"Ames","year":"2013"},{"key":"ref34","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1939-1676.2009.0367.x","article-title":"Acute effects of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs","volume":"23","author":"Sayer","year":"2009"},{"key":"ref35","series-title":"J Pharmacol Exp Ther","first-page":"1087","article-title":"Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic\/pharmacodynamics modeling approach","volume":"292","author":"Toutain","year":"2000"},{"key":"ref36","series-title":"J Vet Pharmacol Ther","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2885.2004.00601.x","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamics relationships for angiotensin-converting enzyme inhibitors","volume":"27","author":"Toutain","year":"2004"},{"issue":"suppl","key":"ref37","series-title":"Am J Cardiol","doi-asserted-by":"publisher","first-page":"1L","DOI":"10.1016\/S0002-9149(01)01878-1","article-title":"The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data","volume":"88","author":"Dzau","year":"2001"},{"key":"ref38","series-title":"J Mol Med","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00109-008-0336-0","article-title":"Update on tissue renin-angiotensin systems","volume":"86","author":"Bader","year":"2008"},{"key":"ref39","first-page":"439","article-title":"Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy","volume":"50","author":"Bader","year":"2010"},{"key":"ref40","series-title":"Biochem Pharmacol","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/0006-2952(95)02038-1","article-title":"Sensitive method for quantification of angiotensin-converting enzyme (ACE) activity in tissue","volume":"50","author":"Cheng Meng","year":"1995"},{"key":"ref41","series-title":"J Pharmacol Toxicol","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1056-8719(97)00099-3","article-title":"Sample dilution: a methodological pitfall in the measurement of tissue but not serum ACE-activity","volume":"39","author":"Koiter","year":"1998"},{"key":"ref42","series-title":"Am J Cardiol","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.amjcard.2004.07.087","article-title":"Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction","volume":"94","author":"Sauer","year":"2004"},{"key":"ref43","series-title":"Am J Cardiol","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.amjcard.2004.08.097","article-title":"Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure","volume":"95","author":"Tu","year":"2005"},{"key":"ref44","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1161\/01.CIR.92.12.3568","article-title":"Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats","volume":"92","author":"Ruzicka","year":"1995"},{"key":"ref45","series-title":"J Am Coll Cardiol","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","article-title":"Neurohormonal and clinical response to high- versus low-dose enalapril therapy in chronic heart failure","volume":"39","author":"Tang","year":"2002"},{"key":"ref46","series-title":"Heart","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/hrt.75.6.576","article-title":"Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure","volume":"75","author":"Davidson","year":"1996"},{"key":"ref47","series-title":"Diabetologia","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004"},{"key":"ref48","series-title":"Hypertension","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways","volume":"59","author":"Briones","year":"2012"},{"key":"ref49","series-title":"Anim Genet","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/age.12260","article-title":"Polymorphisms in the canine and feline renin-angiotensin-aldosterone system genes","volume":"46","author":"Meurs","year":"2015"},{"key":"ref50","series-title":"Clin Exp Hypertens A","first-page":"1233","article-title":"The diagnostic value of the 24 hour integrated concentration of plasma aldosterone","volume":"7","author":"Zadik","year":"1985"},{"key":"ref51","series-title":"Clin Sci (Lond)","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1042\/cs0780605","article-title":"Time-course and relationship of the early changes in renal sodium excretion and aldosterone secretion during dietary sodium restriction in normal man","volume":"78","author":"Carmichael","year":"1990"},{"key":"ref52","series-title":"Scand J Clin Lab Invest","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/00365517809108418","article-title":"Plasma and urinary aldosterone and their interrelations with blood pressure, plasma renin activity and urinary electrolytes in normotensive subjects","volume":"38","author":"Tolagen","year":"1978"},{"key":"ref53","series-title":"Am J Med","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0002-9343(79)90786-1","article-title":"Reliability of screening methods for the diagnosis of primary aldosteronism","volume":"67","author":"Streeten","year":"1979"},{"key":"ref54","series-title":"J Endocrinol","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1677\/joe.0.1240507","article-title":"Effects of dietary sodium restriction and posture on plasma levels of atrial natriuretic peptide, aldosterone and free aldosterone in normal human pregnancy","volume":"124","author":"Steegers","year":"1990"},{"key":"ref55","series-title":"Braunwald's heart disease","first-page":"611","article-title":"Management of heart failure patients with reduced ejection fraction","author":"Mann","year":"2008"},{"key":"ref56","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1939-1676.2003.tb02493.x","article-title":"Intermittent bolus injection versus continuous infusion of furosemide in normal adult Greyhound dogs","volume":"17","author":"Adin","year":"2003"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/76\/12\/ajvr.76.12.1041.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/76\/12\/ajvr.76.12.1041.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/76\/12\/ajvr.76.12.1041.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:36:47Z","timestamp":1741351007000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/76\/12\/ajvr.76.12.1041.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":56,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.76.12.1041","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}